The HCAI4ALL project addressed a critical need in the pharmaceutical industry: the high cost and risk associated with drug discovery and development. Developing new drugs is a lengthy, expensive, and often unsuccessful process, with many promising candidates failing due to unforeseen side effects or lack of efficacy. This high failure rate translates to substantial financial losses and delays in bringing life-saving therapies to patients. HCAI4ALL aimed to de-risk this process by developing and validating an innovative, AI-driven platform specifically targeted at the rapidly growing field of RNA therapeutics.
At the heart of this platform is the QLattice, Abzu's groundbreaking AI technology that provides explainable, accurate, and scalable solutions. Unlike traditional "black box" AI systems, the QLattice offers transparency into its decision-making processes, a crucial factor in sectors like pharmaceuticals where understanding the 'why' behind a prediction is as important as the prediction itself. This explainability fosters trust and acceptance of AI-driven insights, particularly in high-stakes environments.
HCAI4ALL sought to leverage the QLattice, in combination with transformers and specialized tools for RNA therapeutics, to empower researchers to design better compounds, predict and avoid off-target effects and toxicity, and ultimately increase the probability of success for drug candidates. The project's pathway to impact focused on developing a commercially viable AI offering, enabling wider access to this technology. By accelerating drug discovery and development, HCAI4ALL aimed to contribute to improved human health outcomes, a more robust pharmaceutical industry in Europe, and a more responsible and transparent approach to AI in the life sciences. The project's success has the potential to significantly reduce the time and cost associated with bringing new therapies to market, ultimately benefiting patients and driving innovation in a crucial sector of the European economy.
